HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

71.200

-4.900-6.44%

Volume:2.30M

Turnover:166.20M

Market Cap:14.17B

PE:-50.43

High:76.150

Open:76.000

Low:70.350

Close:76.100

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:1.02

T/O Rate:1.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.412

ROE:-27.61%

ROA:-9.92%

PB:9.59

PE(LYR):-50.43

PS:68.50

Loading ...

Overview Company News Filings

Leads Biolabs Highlights R&D Momentum with Six Abstracts Accepted by 2026 ESMO, Including Two Top-Tier Oral Presentations

Bulletin Express

LEADS BIOLABS-B Announces Multiple Research Presentations Selected for Prestigious 2026 ESMO Congress

Nanjing Leads Biolabs Says Six Clinical Studies Win Presentation Slots at 2026 ESMO Meeting

LEADS BIOLABS-B Surges Over 27% in Morning Session as Velixicon® Application Granted Priority Review

Nanjing Leads Biolabs Co - Opamtistomig Bla for Advanced Ep-nec Granted Priority Review by China's Nmpa

THOMSON REUTERS

Nanjing Leads Biolabs Co Ltd: Actively Advancing Relevant Pre-launch Commercialization Preparations

THOMSON REUTERS

Priority Review Granted to Pd-l1/4-1bb Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in Ep-nec

THOMSON REUTERS

Nanjing Leads Biolabs' Cancer Drug Included in China Regulator's Priority Review List

MT Newswires Live

LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma

Nanjing Leads Biolabs Says China Regulator Puts Lbl-024 Ep-nec Filing in Priority Review

Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million

Bulletin Express

LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme

Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme

This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%

Simply Wall St.

Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements

New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development

THOMSON REUTERS

Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio

THOMSON REUTERS

Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing

Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/09887/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":71.2,"timestamp":1787299688011,"preClose":76.1,"halted":0,"volume":2304503,"delay":0,"changeRate":-0.06438896189224694,"floatShares":198000000,"shares":199000000,"eps":-1.4119339130707524,"marketStatus":"Not Yet Opened","change":-4.9,"latestTime":"08-21 16:08:08","open":76,"high":76.15,"low":70.35,"amount":166196792,"amplitude":0.076216,"askPrice":71.2,"askSize":1600,"bidPrice":71.15,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.3734266245324591,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":76.1,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.0243808093189501,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.411934,"volumeRatio":1.0243808093189501,"shares":199000000,"dividePrice":0,"high":76.15,"amplitude":0.076216,"preClose":76.1,"low":70.35,"week52Low":44.72,"pbRate":"9.59","psRate":"68.50","week52High":97.5,"institutionHeld":0,"latestPrice":71.2,"committee":-0.777778,"eps":-1.4119339130707524,"divideRate":0,"volume":2304503,"delay":0,"ttmEps":-1.3734266245324591,"open":76,"prevYearClose":51,"prevWeekClose":73.3,"prevMonthClose":53.4,"prevQuarterClose":49.32,"fiveDayClose":73.3,"twentyDayClose":62.45,"sixtyDayClose":62.95,"earningDate":1788105600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-21","current":-51.841139,"percent":0.129278,"low":-76.458084,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"high":-30.202688,"avg":-41.975218,"sd":9.878337,"marketCap":14161096160},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160}],"updateTime":1787490313304},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140815382","title":"Leads Biolabs Highlights R&D Momentum with Six Abstracts Accepted by 2026 ESMO, Including Two Top-Tier Oral Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=1140815382","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140815382?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:43","pubTimestamp":1783932228,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, HK: 09887) reported that six of its latest oncology studies have been selected for presentation at the 2026 annual meeting of the European Society...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132253753","title":"LEADS BIOLABS-B Announces Multiple Research Presentations Selected for Prestigious 2026 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253753","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253753?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:40","pubTimestamp":1783932034,"startTime":"0","endTime":"0","summary":"The biopharmaceutical company LEADS BIOLABS-B (ASX: 09887) has announced that six of its latest research findings have been accepted for presentation at the 2026 European Society for Medical Oncology...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194299","title":"Nanjing Leads Biolabs Says Six Clinical Studies Win Presentation Slots at 2026 ESMO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651194299?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:37","pubTimestamp":1783931830,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says six clinical studies win presentation slots at 2026 ESMO meetingNanjing Leads Biolabs outlined six studies accepted for presentation at the 2026 ESMO meeting in Madrid on Oc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL6cGTfx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143216016","title":"LEADS BIOLABS-B Surges Over 27% in Morning Session as Velixicon® Application Granted Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1143216016","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143216016?lang=en_us&edition=fundamental","pubTime":"2026-07-13 11:31","pubTimestamp":1783913508,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) surged more than 27% in the morning trading session. At the time of writing, the stock was up 27.40%, trading at HK$63.60 with a turnover of HK$202 million. On July...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650619185","title":"Nanjing Leads Biolabs Co - Opamtistomig Bla for Advanced Ep-nec Granted Priority Review by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2650619185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650619185?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C013:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650318595","title":"Nanjing Leads Biolabs Co Ltd: Actively Advancing Relevant Pre-launch Commercialization Preparations","url":"https://stock-news.laohu8.com/highlight/detail?id=2650318595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650318595?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C013:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185616","title":"Priority Review Granted to Pd-l1/4-1bb Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in Ep-nec","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650185616?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C013:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907770","title":"Nanjing Leads Biolabs' Cancer Drug Included in China Regulator's Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907770","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650907770?lang=en_us&edition=fundamental","pubTime":"2026-07-10 15:08","pubTimestamp":1783667303,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs'  biologics license application for LBL-024 was approved for inclusion in priority review and approval procedure by China's National Medical Products Administration.The drug has been developed as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma, according to a Friday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114500368","title":"LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1114500368","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114500368?lang=en_us&edition=fundamental","pubTime":"2026-07-10 12:34","pubTimestamp":1783658060,"startTime":"0","endTime":"0","summary":"The biologics license application for LEADS BIOLABS-B's (ASX: 09887) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","09887","PD","HK0000252160.HKD","HK0000500386.USD","LU1169589451.USD","LU1169590202.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901310","title":"Nanjing Leads Biolabs Says China Regulator Puts Lbl-024 Ep-nec Filing in Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901310","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901310?lang=en_us&edition=fundamental","pubTime":"2026-07-10 12:28","pubTimestamp":1783657691,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says China regulator puts LBL-024 EP-NEC filing in priority reviewNanjing Leads Biolabs’ China BLA for LBL-024 (opamtistomig) in advanced EP-NEC entered NMPA-CDE priority review.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL8LMSg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189242408","title":"Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1189242408","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189242408?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:25","pubTimestamp":1782984351,"startTime":"0","endTime":"0","summary":"On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183498438","title":"LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1183498438","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183498438?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:20","pubTimestamp":1782908424,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced the granting of a total of 2.2547 million share awards under its H-share incentive scheme.The awards were granted to 149 recipients on July 1, 2026, and are subject to acceptance by the grantees to become effective.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648051015","title":"Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2648051015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648051015?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:45","pubTimestamp":1782906351,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs grants 2,254,691 H-share awards under employee incentive schemeNanjing Leads Biolabs granted 2,254,691 share Awards under its H Share Award Scheme, covering 149 employees.Executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL8wPBMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647575581","title":"This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647575581","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647575581?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:44","pubTimestamp":1782783864,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net sellers in Nanjing Leads Biolabs Co., Ltd.'s ( HKG:9887 ) during the past 12...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119804571","title":"Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1119804571","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119804571?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:59","pubTimestamp":1782439157,"startTime":"0","endTime":"0","summary":"Since last September, the Hong Kong stock market's innovative drug sector has shifted from its previous bull market state, entering a volatile downtrend, with a particularly persistent decline...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107543120","title":"New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1107543120","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107543120?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:26","pubTimestamp":1782429979,"startTime":"0","endTime":"0","summary":"Two major national plans have been announced, focusing on the development of a new energy system by 2030 and a new round of rural new energy vehicle promotion. Key Developments The National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","HK0000306685.HKD","02696","BK1512","LU1808992512.USD","BK4588","HK0000500386.USD","BK1502","80020","HK0000252152.HKD","BK1589","BK1227","09887","HK0000252160.HKD","03998","HK0000165453.HKD","02616","BK4585","BK1109","BK1615","159945","BK1613","HK0000320264.USD","BK1161","00020","BK1500","09879","HK0000306701.USD","BK1113","HK0000320223.HKD","LU1675838814.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874382","title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874382?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646743858","title":"Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2646743858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646743858?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4592","SG9999001176.SGD","LU1066051498.USD","IE00B19Z3581.USD","LU1883839398.USD","SG9999011175.SGD","SG9999013999.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4533","BK4007","BK4568","IE00B3T34201.USD","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","PFE","LU0306806265.USD","LU0456855351.SGD","LU2596442595.SGD","IE00BLSP4452.SGD","HK0000252152.HKD","LU0868494617.USD","LU1066053197.SGD","LU1023059063.AUD","LU1894683264.USD","BK4585","LU0321505439.SGD","LU1057294990.SGD","BK1161","HK0000500386.USD","SG9999001176.USD","SG9999002232.USD","SG9999002224.SGD","IE00BBT3K403.USD","LU0289739699.SGD","LU1894683348.USD","BK4550","LU0234572021.USD","LU0321505868.SGD","LU0058720904.USD","HK0000252160.HKD","BK4588","LU0225771236.USD","LU0306807586.USD","BK4534","IE00BLSP4239.USD","09887","BK4599","LU0985481810.HKD","IE0002270589.USD","LU0225284248.USD","IE000M9KFDE8.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879406","title":"Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879406","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879406?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:01","pubTimestamp":1782381702,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says partner Oblenio moves LBL-051 toward clinical trial start after US$62 million Series B financingNanjing Leads Biolabs’ partner Oblenio Bio closed an oversubscribed USD 62 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL4gVVJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113955695","title":"Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113955695","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113955695?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:04","pubTimestamp":1780661065,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced the successful completion of its H-share full circulation programme, converting 44.39 million previously unlisted domestic shares into H...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":131,"code":"91000000","status":"200"}]}}